High performance plasma amyloid-β biomarkers for Alzheimer's disease

被引:1249
作者
Nakamura, Akinori [1 ]
Kaneko, Naoki [2 ]
Villemagne, Victor L. [3 ,4 ]
Kato, Takashi [1 ,5 ]
Doecke, James [6 ]
Dore, Vincent [3 ,6 ]
Fowler, Chris [4 ]
Li, Qiao-Xin [4 ]
Martins, Ralph [7 ]
Rowe, Christopher [3 ,4 ]
Tomita, Taisuke [8 ]
Matsuzaki, Katsumi [9 ]
Ishii, Kenji [10 ]
Ishii, Kazunari [11 ]
Arahata, Yutaka [5 ]
Iwamoto, Shinichi [2 ]
Ito, Kengo [1 ,5 ]
Tanaka, Koichi [2 ]
Masters, Colin L. [4 ]
Yanagisawa, Katsuhiko [1 ]
机构
[1] Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dementia, Obu, Aichi 4748511, Japan
[2] Shimadzu Co Ltd, Koichi Tanaka Mass Spectrometry Res Lab, Kyoto 6048511, Japan
[3] Austin Hlth, Dept Mol Imaging & Therapy, Ctr PET, Heidelberg, Vic 3084, Australia
[4] Univ Melbourne, Florey Inst, Parkville, Vic 3010, Australia
[5] Natl Hosp Geriatr Med, Natl Ctr Geriatr & Gerontol, Obu, Aichi 4748511, Japan
[6] CSIRO, Hlth & Biosecur, Brisbane, Qld 4029, Australia
[7] Edith Cowan Univ, Joondalup, WA 6027, Australia
[8] Univ Tokyo, Lab Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan
[9] Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan
[10] Tokyo Metropolitan Inst Gerontol, Team Neuroimaging Res, Tokyo 1730015, Japan
[11] Kindai Univ, Fac Med, Dept Radiol, Osaka 5898511, Japan
基金
英国医学研究理事会;
关键词
MILD COGNITIVE IMPAIRMENT; BLOOD-BASED BIOMARKERS; CEREBROSPINAL-FLUID; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; QUANTIFICATION; PET; RECOMMENDATIONS; PEPTIDES;
D O I
10.1038/nature25456
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease(1,2), supportive biomarker information is necessary. The only validated methods for identifying amyloid-beta deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-beta positron-emission tomography (PET) imaging or measurement of amyloid-beta in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable(3,4). Despite much effort(3-7), to our knowledge, no study has validated the clinical utility of blood-based amyloid-beta markers. Here we demonstrate the measurement of high-performance plasma amyloid-beta biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-beta precursor protein (APP)(669-711)/amyloid-beta (A beta)(1-42) and A beta(1-40)/A beta(1-42) ratios, and their composites, to predict individual brain amyloid-beta-positive or -negative status was determined by amyloid-beta-PET imaging and tested using two independent data sets: a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252 including 111 individuals diagnosed using C-11-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain amyloid-beta burden. In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves (AUCs) in both data sets (discovery, 96.7%, n = 121 and validation, 94.1%, n = 111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth. Furthermore, test biomarkers were correlated with amyloid-beta-PET burden and levels of A beta(1-42) in cerebrospinal fluid. These results demonstrate the potential clinical utility of plasma biomarkers in predicting brain amyloid-beta burden at an individual level. These plasma biomarkers also have cost-benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening.
引用
收藏
页码:249 / +
页数:24
相关论文
共 48 条
[1]   The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].
Albert, Marilyn S. ;
DeKosky, Steven T. ;
Dickson, Dennis ;
Dubois, Bruno ;
Feldman, Howard H. ;
Fox, Nick C. ;
Gamst, Anthony ;
Holtzman, David M. ;
Jagust, William J. ;
Petersen, Ronald C. ;
Snyder, Peter J. ;
Carrillo, Maria C. ;
Thies, Bill ;
Phelps, Creighton H. .
ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279
[2]  
[Anonymous], 2014, Adv Res
[3]   Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study [J].
Boccardi, Marina ;
Altomare, Daniele ;
Ferrari, Clarissa ;
Festari, Cristina ;
Guerra, Ugo Paolo ;
Paghera, Barbara ;
Pizzocaro, Claudio ;
Lussignoli, Giulia ;
Geroldi, Cristina ;
Zanetti, Orazio ;
Cotelli, Maria Sofia ;
Turla, Marinella ;
Borroni, Barbara ;
Rozzini, Luca ;
Mirabile, Dario ;
Defanti, Carlo ;
Gennuso, Michele ;
Prelle, Alessandro ;
Gentile, Simona ;
Morandi, Alessandro ;
Vollaro, Stefano ;
Dalla Volta, Giorgio ;
Bianchetti, Angelo ;
Conti, Marta Zaffira ;
Cappuccio, Melania ;
Carbone, Pasqualina ;
Bellandi, Daniele ;
Abruzzi, Luciano ;
Bettoni, Luigi ;
Villani, Daniele ;
Raimondi, Maria Clara ;
Lanari, Alessia ;
Ciccone, Alfonso ;
Facchi, Emanuela ;
Di Fazio, Ignazio ;
Rozzini, Renzo ;
Boffelli, Stefano ;
Manzoni, Laura ;
Salvi, Giovanni Pietro ;
Cavaliere, Sabina ;
Belotti, Gloria ;
Avanzi, Stefano ;
Pasqualetti, Patrizio ;
Muscio, Cristina ;
Padovani, Alessandro ;
Frisoni, Giovanni B. .
JAMA NEUROLOGY, 2016, 73 (12) :1417-1424
[4]   Comparison of MR-less PiB SUVR quantification methods [J].
Bourgeat, Pierrick ;
Villemagne, Victor L. ;
Dore, Vincent ;
Brown, Belinda ;
Macaulay, S. Lance ;
Martins, Ralph ;
Masters, Colin L. ;
Ames, David ;
Ellis, Kathryn ;
Rowe, Christopher C. ;
Salvado, Olivier ;
Fripp, Jurgen .
NEUROBIOLOGY OF AGING, 2015, 36 :S159-S166
[5]   Clinical Impact of Amyloid Positron Emission Tomography-Is It Worth the Cost? [J].
Caselli, Richard J. ;
Woodruff, Bryan K. .
JAMA NEUROLOGY, 2016, 73 (12) :1396-1398
[6]   Use of Florbetapir-PET for Imaging β-Amyloid Pathology [J].
Clark, Christopher M. ;
Schneider, Julie A. ;
Bedell, Barry J. ;
Beach, Thomas G. ;
Bilker, Warren B. ;
Mintun, Mark A. ;
Pontecorvo, Michael J. ;
Hefti, Franz ;
Carpenter, Alan P. ;
Flitter, Matthew L. ;
Krautkramer, Michael J. ;
Kung, Hank F. ;
Coleman, R. Edward ;
Doraiswamy, P. Murali ;
Fleisher, Adam S. ;
Sabbagh, Marwan N. ;
Sadowsky, Carl H. ;
Reiman, P. Eric M. ;
Zehntner, Simone P. ;
Skovronsky, Daniel M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03) :275-283
[7]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[8]   The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease [J].
Ellis, Kathryn A. ;
Bush, Ashley I. ;
Darby, David ;
De Fazio, Daniela ;
Foster, Jonathan ;
Hudson, Peter ;
Lautenschlager, Nicola I. ;
Lenzo, Nat ;
Martins, Ralph N. ;
Maruff, Paul ;
Masters, Colin ;
Milner, Andrew ;
Pike, Kerryn ;
Rowe, Christopher ;
Savage, Greg ;
Szoeke, Cassandra ;
Taddei, Kevin ;
Villemagne, Victor ;
Woodward, Michael ;
Ames, David .
INTERNATIONAL PSYCHOGERIATRICS, 2009, 21 (04) :672-687
[9]   Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology [J].
Fagan, Anne M. ;
Shaw, Leslie M. ;
Xiong, Chengjie ;
Vanderstichele, Hugo ;
Mintun, Mark A. ;
Trojanowski, John Q. ;
Coart, Els ;
Morris, John C. ;
Holtzman, David M. .
ARCHIVES OF NEUROLOGY, 2011, 68 (09) :1137-1144
[10]  
Gelfanova Valentina, 2007, Briefings in Functional Genomics & Proteomics, V6, P149, DOI 10.1093/bfgp/elm010